System-level BER test and jitter extraction of a 6.4Gbps parallel chip to chip bus on the first generation cell processor

Author(s):  
C. Madden ◽  
Kyung Suk Oh ◽  
A. Torres ◽  
Jie Shen ◽  
J. Kizer ◽  
...  
2010 ◽  
Vol 49 (02) ◽  
pp. 173-185 ◽  
Author(s):  
H. Tanaka

Summary Objectives: Recent important advances in the human genomics and post-genomic “omics” are now bringing about a new medical care which we call “omics-based medicine”. In this article, we investigated the development and future possibilities of omics-based medicine. Methods: We divided the development of omics-based medicine into three generations in order to clarify the main clinical goals and characteristics of informatics method of each generation, together with its future possibilities. Results: The first generation of omics-based medicine started with “genomic medicine” based on the inborn individual differences of genome. It has opened the study of genetic polymorphism of the diseases and promoted the personalized medication based on the pharmacogenetic/pharmacogenomic difference of the drug response. In the second generation of omics-based medicine, owing to the advances in the high-throughput technology, vast amount of the various post-genomic disease omics data containing comprehensive molecular information of diseased somatic cells has become available. It reflects the ongoing state of diseases more closely and enables the predictive medicine such as prognosis prediction of disease by applying the data-driven analysis. Finally, due to the rapidly growing knowledge about the cellular molecular network, system-level understanding of the disease, called systems pathology, becomes possible. It can fully exploit the substantial contents of disease omics and will lead to a comprehensive understanding of disease process by using model-driven analysis. Conclusion: Omics-based medicine and systems pathology will realize a new personalized and predictive medicine.


2006 ◽  
Vol 41 (1) ◽  
pp. 179-196 ◽  
Author(s):  
D.C. Pham ◽  
T. Aipperspach ◽  
D. Boerstler ◽  
M. Bolliger ◽  
R. Chaudhry ◽  
...  

2020 ◽  
Author(s):  
Donna M. Lisi

Anticholinergic medications are widely used in older adults and are a common source of adverse events in this population. Common drug classes include antiarrhythmics, antidepressants, antiemetics, first generation antihistamines, urinary incontinence antimuscarinic agents, antiparkinsonian agents, antipsychotics, antispasmodics, and skeletal muscle relaxants. These drugs have been associated with delirium, cognitive impairment, sedation, dizziness, falls, fracture, constipation, urinary retention, blurred vision, tachycardia and dry mouth. If possible, these drugs should be avoided in older adults or less toxic agents within the class should be utilized. This chapter will explore the mechanism of action of anticholinergic drugs at both the cellular and organ system level; discuss how to assess for anticholinergic drug burden; list medications with anticholinergic effects as identified in the Beer’s criteria on potentially inappropriate medication use in older adults; review anticholinergic drug–drug interactions; describe contraindications to the use of anticholinergic agents; and explore practical considerations such as the availability of these substances in nonprescription medications, their use at end of life and deprescribing.


Author(s):  
M. Riley ◽  
L. Bushard ◽  
N. Chelstrom ◽  
N. Kiryu ◽  
S. Ferguson

Sign in / Sign up

Export Citation Format

Share Document